本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

再鼎医药

29.71
+0.87003.02%
盘后29.30-0.4100-1.38%16:09 EDT
成交量:69.61万
成交额:2,048.91万
市值:32.57亿
市盈率:-11.43
高:29.91
开:28.64
低:28.63
收:28.84
数据加载中...
2024/04/03

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/04/03

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/03/15

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/03/15

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/02/27

年度报告

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
2024/02/27

重要事件披露

Form 8-K - Current report
2024/02/17

SEC问询函

Form CORRESP - Correspondence
2024/02/09

超过5%披露

Form SC 13G - Statement of acquisition of beneficial ownership by individuals
2024/02/08

重要事件披露

Form 8-K - Current report
2024/02/08

超过5%披露

Form SC 13G - Statement of acquisition of beneficial ownership by individuals
2024/02/01

超过5%披露

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
2024/02/01

SEC问询函

Form CORRESP - Correspondence
2024/01/06

SEC问询函

Form CORRESP - Correspondence
2024/01/03

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/01/03

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/01/03

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/01/03

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2023/12/22

[修订]年度报告

Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
2023/12/04

SEC问询函

Form CORRESP - Correspondence
2023/11/08

季度报告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]